支持性心理治疗与帕罗西汀合并米氮平联合治疗难治性抑郁症的对照研究

Comparative study of supportive psychotherapy combined with paroxetine and mirtazapine in treatment of refractory depression

目的探讨支持性心理治疗与帕罗西汀合并米氮平联合治疗难治性抑郁症的疗效。方法选取2013年3月至2015年2月于我院精神病科门诊及住院部收治的难治性抑郁症患者184例,将其随机分为两组,分别是治疗组(支持性心理治疗联合帕罗西汀合并米氮平)和对照组(帕罗西汀合并米氮平),各92例,连续治疗8周,治疗前后采用汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)评定患者的抑郁症状,然后比较两组间的差异及临床疗效。结果治疗8周后,治疗组的HAMD评分显著低于对照组(P<0.01),治疗组的总有效率亦明显高于对照组(P<0.05),差异均具有统计学意义。结论支持性心理治疗联合帕罗西汀合并米氮平联合疗法可有效改善难治性抑郁症患者的精神症状,促进其身心健康,从而提高临床疗效,值得深入推广。

Objective To investigate the efficacy of supportive psychotherapy combined with paroxetine and mirtazapine in the treatment of refractory depression. Methods From March 2013 to February 2015,184 patients with refractory depression who were in our hospital department of Endocrinology outpatient and inpatient,were randomly divided into two groups,one was the treatment group（ supportive psychological treatment combined with paroxetine and mirtazapine） and the other was control group（ paroxetine and mirtazapine）. All of them were92 cases. Hamilton depression rating table（ Hamilton Depression Scale,HAMD） were assessed for depressive symptoms before and after the treatment and their differences and clinical efficacy were compared between the two groups after 8 weeks of continuous treatment. Results After 8 weeks,the HAMD score of the treatment group was significantly lower than that of the control group（ P 〈0. 01）,the total effective rate was obviously higher than the control group（ P〈0. 05）,while all of them had significant differences. Conclusions The supportive psychotherapy combined with paroxetine and mirtazapine mirtazapine can effectively improve refractory depression patients of psychiatric symptoms and then promote their physical and mental health,as well as improve the clinical efficacy,which is worthy of further promotion.